Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Exploratory Study of Conversion Surgery for Apatinib in Combination With Oxaliplatin/S-1(SOX) for Patients With Unresectable Gastric Cancer

X
Trial Profile

The Exploratory Study of Conversion Surgery for Apatinib in Combination With Oxaliplatin/S-1(SOX) for Patients With Unresectable Gastric Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Oxaliplatin (Primary) ; Rivoceranib (Primary)
  • Indications Adenocarcinoma; Gastric cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 May 2019 Status changed from recruiting to completed.
    • 31 May 2019 Results assessing feasibility of SOX regimen in combination with apatinib in advanced gastric cancer patients, published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).
    • 20 Jan 2018 First patients were enrolled in Dec 2016 and Data analysis is planned in Nov 2018, according to the trial design presented at the 2018 Gastrointestinal Cancers Symposium
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top